Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Decreases By 98.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant decline in short interest in October. As of October 31st, there was short interest totalling 100 shares, a decline of 98.1% from the October 15th total of 5,200 shares. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is currently 0.0 days.

SAB Biotherapeutics Price Performance

SABSW stock remained flat at $0.05 during midday trading on Thursday. 11,961 shares of the company’s stock were exchanged, compared to its average volume of 19,536. The stock’s 50 day simple moving average is $0.04 and its 200-day simple moving average is $0.04. SAB Biotherapeutics has a 1 year low of $0.01 and a 1 year high of $0.19.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.